Literature DB >> 17403707

Dose of alfentanil needed to obtain optimal intubation conditions during rapid-sequence induction of anaesthesia with thiopentone and rocuronium.

M H Abou-Arab1, T Heier, J E Caldwell.   

Abstract

BACKGROUND: The primary aim of the present study was to determine the dose of alfentanil that must be added to a rapid-sequence induction (RSI) regimen using thiopentone and rocuronium to obtain optimal intubation conditions in >95% of the individuals.
METHODS: A total of 60 ASA I patients were randomly allocated to five different alfentanil dose groups (0, 15, 30, 45, or 60 microg kg-1). A blinded dose of alfentanil followed by thiopentone 4 mg kg-1 and rocuronium 1 mg kg-1 was administered in rapid succession, and tracheal intubation was attempted 40 s thereafter. The relationship between the alfentanil dose and the probability of optimal intubation conditions was determined by non-linear logistic regression analysis. Blood pressure (BP) changes were recorded continuously using an intra-arterial catheter.
RESULTS: The success rate of optimal intubation conditions increased with increasing doses of alfentanil. The alfentanil dose needed to obtain optimal intubation conditions in >95% of the patients was 36.4 (CI 33.4-39.4) microg kg-1. In 12 patients, the systolic BP declined to <90 mm Hg during the 3 min immediately after intubation.
CONCLUSION: Adding 36-40 microg kg-1 alfentanil to a regimen of thiopentone and rocuronium during RSI of anaesthesia may significantly increase the success rate of optimal intubation conditions. Significant hypotension requiring vasopressor treatment may occur.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403707     DOI: 10.1093/bja/aem064

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Comparison of the effect of fentanyl, sufentanil, alfentanil and remifentanil on cardiovascular response to tracheal intubation in children.

Authors:  Seyed-Mohamad Mireskandari; Navid Abulahrar; Mohamad-Esmaeil Darabi; Iman Rahimi; Fatemeh Haji-Mohamadi; Ali Movafegh
Journal:  Iran J Pediatr       Date:  2011-06       Impact factor: 0.364

2.  Changes in intraocular pressure following administration of suxamethonium and endotracheal intubation: Influence of dexmedetomidine premedication.

Authors:  Chandan Kumar Pal; Manjushree Ray; Anjana Sen; Bimal Hajra; Dipankar Mukherjee; Anil Kumar Ghanta
Journal:  Indian J Anaesth       Date:  2011-11

3.  Attenuation of pressor response and dose sparing of opioids and anaesthetics with pre-operative dexmedetomidine.

Authors:  Sukhminder Jit Singh Bajwa; Jasbir Kaur; Amarjit Singh; Ss Parmar; Gurpreet Singh; Ashish Kulshrestha; Sachin Gupta; Veenita Sharma; Aparajita Panda
Journal:  Indian J Anaesth       Date:  2012-03

4.  Effects of conventional vs high-dose rocuronium on the QTc interval during anesthesia induction and intubation in patients undergoing coronary artery surgery: a randomized, double-blind, parallel trial.

Authors:  T Öztürk; D Ağdanli; Ö Bayturan; C Çikrikci; G T Keleş
Journal:  Braz J Med Biol Res       Date:  2015-02-24       Impact factor: 2.590

5.  Attenuation of hemodynamic response to laryngoscopy and orotracheal intubation using intravenous clonidine.

Authors:  Sakshi Arora; Anita Kulkarni; Ajay Kumar Bhargava
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Jan-Mar

6.  To Evaluate the Efficacy of Intravenous Infusion of Dexmedetomidine as Premedication in Attenuating the Rise of Intraocular Pressure Caused by Succinylcholine in Patients Undergoing Rapid Sequence Induction for General Anesthesia: A Randomized Study.

Authors:  Raj Bahadur Singh; Sanjay Choubey; Saurabh Mishra
Journal:  Anesth Essays Res       Date:  2017 Oct-Dec

7.  Effect of low-dose ketamine versus fentanyl on attenuating the haemodynamic response to laryngoscopy and endotracheal intubation in patients undergoing general anaesthesia: a prospective, double-blinded, randomised controlled trial.

Authors:  Angela Ongewe; Vitalis Mung'ayi; Rajpreet Bal
Journal:  Afr Health Sci       Date:  2019-09       Impact factor: 0.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.